# PeptideScanner evidence objects: Rusfertide

Every published version of the records placed with Rusfertide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/rusfertide.json. Selected public evidence only; not medical advice.

- Objects: 11
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct04202965-rusfertide-v1"></a>

## ClinicalTrials.gov record NCT04202965

> PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.

- Evidence object: `story:clinicaltrials-gov-nct04202965-rusfertide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04202965-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct04202965-rusfertide-v1
- Content SHA-256: `9326a1a8b11ef684625520f39ba39a692a85db057fa2c6e7e2110e6b6e344c3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04202965 ([`ctg-observation-nct04202965-2025-08-20-a19784d777f9`](#source-ctg-observation-nct04202965-2025-08-20-a19784d777f9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct04202965-2025-08-20-a19784d777f9`](#source-ctg-observation-nct04202965-2025-08-20-a19784d777f9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct04202965-2025-08-20-a19784d777f9`](#source-ctg-observation-nct04202965-2025-08-20-a19784d777f9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04202965-2025-08-20-a19784d777f9`](#source-ctg-observation-nct04202965-2025-08-20-a19784d777f9))

### Sources

<a id="source-ctg-observation-nct04202965-2025-08-20-a19784d777f9"></a>
- **ClinicalTrials.gov record NCT04202965 · retained source version 2025-08-20:a19784d777f9f9fd9442eb137d4d318e0da9ab7310a6c27f169a2c6eafe8534c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04202965) (`ctg-observation-nct04202965-2025-08-20-a19784d777f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04202965." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct04202965-rusfertide-v1 SHA-256: 9326a1a8b11ef684625520f39ba39a692a85db057fa2c6e7e2110e6b6e344c3e.

---

<a id="clinicaltrials-gov-nct04767802-rusfertide-v1"></a>

## ClinicalTrials.gov record NCT04767802

> PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.

- Evidence object: `story:clinicaltrials-gov-nct04767802-rusfertide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04767802-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct04767802-rusfertide-v1
- Content SHA-256: `ffa16b2a071263cf002c85c6c27c152b4b0a443c10ccd38dfb16570c129d5080`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04767802 ([`ctg-observation-nct04767802-2024-03-18-fc029104809b`](#source-ctg-observation-nct04767802-2024-03-18-fc029104809b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct04767802-2024-03-18-fc029104809b`](#source-ctg-observation-nct04767802-2024-03-18-fc029104809b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct04767802-2024-03-18-fc029104809b`](#source-ctg-observation-nct04767802-2024-03-18-fc029104809b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04767802-2024-03-18-fc029104809b`](#source-ctg-observation-nct04767802-2024-03-18-fc029104809b))

### Sources

<a id="source-ctg-observation-nct04767802-2024-03-18-fc029104809b"></a>
- **ClinicalTrials.gov record NCT04767802 · retained source version 2024-03-18:fc029104809b3957d08b3efb82597002ffd571e955134c4d5e0e878ecde98e17** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04767802) (`ctg-observation-nct04767802-2024-03-18-fc029104809b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04767802." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct04767802-rusfertide-v1 SHA-256: ffa16b2a071263cf002c85c6c27c152b4b0a443c10ccd38dfb16570c129d5080.

---

<a id="clinicaltrials-gov-nct05210790-rusfertide-v1"></a>

## ClinicalTrials.gov record NCT05210790

> PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.

- Evidence object: `story:clinicaltrials-gov-nct05210790-rusfertide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05210790-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct05210790-rusfertide-v1
- Content SHA-256: `93cb14f71fe1a295b3764ab93a4d6af439a2a1a62cd35cf9705dadf599296bb1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05210790 ([`ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91`](#source-ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91`](#source-ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91`](#source-ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91`](#source-ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91))

### Sources

<a id="source-ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91"></a>
- **ClinicalTrials.gov record NCT05210790 · retained source version 2026-10-19:da5ff0cdcd91da4dc3c42873f10463ce62721a885b3a666e1fd26acd30ebdc5e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05210790) (`ctg-observation-nct05210790-2026-10-19-da5ff0cdcd91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05210790." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct05210790-rusfertide-v1 SHA-256: 93cb14f71fe1a295b3764ab93a4d6af439a2a1a62cd35cf9705dadf599296bb1.

---

<a id="clinicaltrials-gov-nct07648030-rusfertide-v1"></a>

## ClinicalTrials.gov record NCT07648030

> PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide.

- Evidence object: `story:clinicaltrials-gov-nct07648030-rusfertide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07648030-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct07648030-rusfertide-v1
- Content SHA-256: `f210d4d656d24cf41182b9d597dddaef25b4152cba5198fc4d4b16bab7ce0731`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07648030 ([`ctg-observation-nct07648030-2026-10-02-c1992cd781b4`](#source-ctg-observation-nct07648030-2026-10-02-c1992cd781b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct07648030-2026-10-02-c1992cd781b4`](#source-ctg-observation-nct07648030-2026-10-02-c1992cd781b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct07648030-2026-10-02-c1992cd781b4`](#source-ctg-observation-nct07648030-2026-10-02-c1992cd781b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07648030-2026-10-02-c1992cd781b4`](#source-ctg-observation-nct07648030-2026-10-02-c1992cd781b4))

### Sources

<a id="source-ctg-observation-nct07648030-2026-10-02-c1992cd781b4"></a>
- **ClinicalTrials.gov record NCT07648030 · retained source version 2026-10-02:c1992cd781b489c46984212132030dc5568b1d2e29bfff119e263d9484019cf9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07648030) (`ctg-observation-nct07648030-2026-10-02-c1992cd781b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07648030." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct07648030-rusfertide-v1 SHA-256: f210d4d656d24cf41182b9d597dddaef25b4152cba5198fc4d4b16bab7ce0731.

---

<a id="clinicaltrials-gov-nct07765602-rusfertide-v1"></a>

## ClinicalTrials.gov record NCT07765602

> PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide.

- Evidence object: `story:clinicaltrials-gov-nct07765602-rusfertide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07765602-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct07765602-rusfertide-v1
- Content SHA-256: `2bced0061d36780b539c19eb7a4a7957e4257d3c884c8ab529f2898398aee627`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07765602 ([`ctg-observation-nct07765602-2026-08-28-ffdf379822df`](#source-ctg-observation-nct07765602-2026-08-28-ffdf379822df))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct07765602-2026-08-28-ffdf379822df`](#source-ctg-observation-nct07765602-2026-08-28-ffdf379822df))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide. ([`ctg-observation-nct07765602-2026-08-28-ffdf379822df`](#source-ctg-observation-nct07765602-2026-08-28-ffdf379822df))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07765602-2026-08-28-ffdf379822df`](#source-ctg-observation-nct07765602-2026-08-28-ffdf379822df))

### Sources

<a id="source-ctg-observation-nct07765602-2026-08-28-ffdf379822df"></a>
- **ClinicalTrials.gov record NCT07765602 · retained source version 2026-08-28:ffdf379822df0a0743dc9260c7e351b9c668791c6d7d06525093a6daf58008ef** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07765602) (`ctg-observation-nct07765602-2026-08-28-ffdf379822df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07765602." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#clinicaltrials-gov-nct07765602-rusfertide-v1 SHA-256: 2bced0061d36780b539c19eb7a4a7957e4257d3c884c8ab529f2898398aee627.

---

<a id="fda-drugs-nda220605-v1"></a>

## Drugs@FDA application NDA220605

> The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda220605:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda220605/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#fda-drugs-nda220605-v1
- Content SHA-256: `8d6f8376f68b21275cfa0ae9ce4c4a9a5c543a67bc1915e4073f83da0a13a096`

### Claims and source pins

#### Headline

Drugs@FDA application NDA220605 ([`fda-drugs-nda220605-2026-08-28-a7ed76fa3483`](#source-fda-drugs-nda220605-2026-08-28-a7ed76fa3483))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients. ([`fda-drugs-nda220605-2026-08-28-a7ed76fa3483`](#source-fda-drugs-nda220605-2026-08-28-a7ed76fa3483))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients. ([`fda-drugs-nda220605-2026-08-28-a7ed76fa3483`](#source-fda-drugs-nda220605-2026-08-28-a7ed76fa3483))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda220605-2026-08-28-a7ed76fa3483`](#source-fda-drugs-nda220605-2026-08-28-a7ed76fa3483))

### Sources

<a id="source-fda-drugs-nda220605-2026-08-28-a7ed76fa3483"></a>
- **Drugs@FDA application NDA220605 · original submission status AP · 2026-08-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA220605%22&limit=1) (`fda-drugs-nda220605-2026-08-28-a7ed76fa3483`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA220605." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#fda-drugs-nda220605-v1 SHA-256: 8d6f8376f68b21275cfa0ae9ce4c4a9a5c543a67bc1915e4073f83da0a13a096.

---

<a id="pubmed-pmid-37863080-rusfertide-v1"></a>

## Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.

> PubMed lists PMID 37863080 in The lancet. Gastroenterology & hepatology as Clinical Trial, Phase II, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37863080-rusfertide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37863080-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-37863080-rusfertide-v1
- Content SHA-256: `6ec18741ca091363c9106d931cb4748e89f14ee40da35e344c87e3a266926a67`

### Claims and source pins

#### Headline

Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. ([`pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54`](#source-pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54))

#### Summary

PubMed lists PMID 37863080 in The lancet. Gastroenterology & hepatology as Clinical Trial, Phase II, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54`](#source-pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54))

#### Paragraph 1

PubMed lists PMID 37863080 in The lancet. Gastroenterology & hepatology as Clinical Trial, Phase II, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54`](#source-pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54`](#source-pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54))

### Sources

<a id="source-pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54"></a>
- **Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. · retained source version 1:2025-06-05:current:8b375ba88f541f877d70569b68c87e9a19561a42d5828577a4a9da956b787d8c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37863080/) (`pubmed-observation-pmid-37863080-2025-06-05-8b375ba88f54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-37863080-rusfertide-v1 SHA-256: 6ec18741ca091363c9106d931cb4748e89f14ee40da35e344c87e3a266926a67.

---

<a id="pubmed-pmid-38340748-rusfertide-v1"></a>

## Rusfertide for iron overload in haemochromatosis - Authors' reply.

> PubMed lists PMID 38340748 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38340748-rusfertide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38340748-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-38340748-rusfertide-v1
- Content SHA-256: `65460be8a4e7d473718761daaa9bb01d4e2141cafd7eb9f2cbdb4f6ab3c57bb9`

### Claims and source pins

#### Headline

Rusfertide for iron overload in haemochromatosis - Authors' reply. ([`pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d`](#source-pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d))

#### Summary

PubMed lists PMID 38340748 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d`](#source-pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d))

#### Paragraph 1

PubMed lists PMID 38340748 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d`](#source-pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d`](#source-pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d))

### Sources

<a id="source-pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d"></a>
- **Rusfertide for iron overload in haemochromatosis - Authors' reply. · retained source version 1:2025-06-05:current:64d7cba56a9debd9c6f9f5b6efe3dd35d35a36fb0a2b7b467fdaf227348d8cb5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38340748/) (`pubmed-observation-pmid-38340748-2025-06-05-64d7cba56a9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rusfertide for iron overload in haemochromatosis - Authors' reply." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-38340748-rusfertide-v1 SHA-256: 65460be8a4e7d473718761daaa9bb01d4e2141cafd7eb9f2cbdb4f6ab3c57bb9.

---

<a id="pubmed-pmid-38340749-rusfertide-v1"></a>

## Rusfertide for iron overload in haemochromatosis.

> PubMed lists PMID 38340749 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38340749-rusfertide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38340749-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-38340749-rusfertide-v1
- Content SHA-256: `a70a0fb6b7f4cb02d2ab900e8f6aff84cb5a15af849b580220406adb1e8894d1`

### Claims and source pins

#### Headline

Rusfertide for iron overload in haemochromatosis. ([`pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0`](#source-pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0))

#### Summary

PubMed lists PMID 38340749 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0`](#source-pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0))

#### Paragraph 1

PubMed lists PMID 38340749 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0`](#source-pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0`](#source-pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0))

### Sources

<a id="source-pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0"></a>
- **Rusfertide for iron overload in haemochromatosis. · retained source version 1:2025-06-05:current:cc2a34cd5eb0b7b41c31e13be45e4389350dce11af4253d615ebbf3ca151a338** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38340749/) (`pubmed-observation-pmid-38340749-2025-06-05-cc2a34cd5eb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rusfertide for iron overload in haemochromatosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-38340749-rusfertide-v1 SHA-256: a70a0fb6b7f4cb02d2ab900e8f6aff84cb5a15af849b580220406adb1e8894d1.

---

<a id="pubmed-pmid-42868322-rusfertide-v1"></a>

## VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

> PubMed lists PMID 42868322 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42868322-rusfertide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42868322-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-42868322-rusfertide-v1
- Content SHA-256: `492630d519a7bf5db63959aa96d67173036404f649ff187efc20e7add29d3ed4`

### Claims and source pins

#### Headline

VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. ([`pubmed-observation-pmid-42868322-2026-10-13-669295a84451`](#source-pubmed-observation-pmid-42868322-2026-10-13-669295a84451))

#### Summary

PubMed lists PMID 42868322 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42868322-2026-10-13-669295a84451`](#source-pubmed-observation-pmid-42868322-2026-10-13-669295a84451))

#### Paragraph 1

PubMed lists PMID 42868322 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42868322-2026-10-13-669295a84451`](#source-pubmed-observation-pmid-42868322-2026-10-13-669295a84451))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42868322-2026-10-13-669295a84451`](#source-pubmed-observation-pmid-42868322-2026-10-13-669295a84451))

### Sources

<a id="source-pubmed-observation-pmid-42868322-2026-10-13-669295a84451"></a>
- **VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. · retained source version 1:2026-10-13:current:669295a84451d46a3631e2ef9c55cecfebed46ab2dc6f1ca83a466e02fbbbba5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42868322/) (`pubmed-observation-pmid-42868322-2026-10-13-669295a84451`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-42868322-rusfertide-v1 SHA-256: 492630d519a7bf5db63959aa96d67173036404f649ff187efc20e7add29d3ed4.

---

<a id="pubmed-pmid-42958870-rusfertide-v1"></a>

## Rusfertide for the treatment of polycythemia vera.

> PubMed lists PMID 42958870 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-31 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42958870-rusfertide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42958870-rusfertide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-42958870-rusfertide-v1
- Content SHA-256: `362e732d36631d8a1c9df74b4f1e56e812cf65e7d55f548ca5b7a974298f1205`

### Claims and source pins

#### Headline

Rusfertide for the treatment of polycythemia vera. ([`pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1`](#source-pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1))

#### Summary

PubMed lists PMID 42958870 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-31 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1`](#source-pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1))

#### Paragraph 1

PubMed lists PMID 42958870 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-31 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1`](#source-pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1`](#source-pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1))

### Sources

<a id="source-pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1"></a>
- **Rusfertide for the treatment of polycythemia vera. · retained source version 1:2026-10-31:current:9cfe6fbaf2e1ddf16dce802b6db311ea7fe5404ec9b888f0ef2bedc88e3dd4c5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42958870/) (`pubmed-observation-pmid-42958870-2026-10-31-9cfe6fbaf2e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rusfertide for the treatment of polycythemia vera." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/rusfertide.json#pubmed-pmid-42958870-rusfertide-v1 SHA-256: 362e732d36631d8a1c9df74b4f1e56e812cf65e7d55f548ca5b7a974298f1205.

